

George Bozas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8018619/publications.pdf>

Version: 2024-02-01

51
papers

2,134
citations

430442

18
h-index

223531

46
g-index

52
all docs

52
docs citations

52
times ranked

2559
citing authors

#	ARTICLE	IF	CITATIONS
1	The prognostic value of respiratory symptoms and performance status in ambulatory cancer patients and unsuspected pulmonary embolism; analysis of an international, prospective, observational cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2791-2800.	1.9	7
2	Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis. <i>Lancet Haematology</i> , 2020, 7, e746-e755.	2.2	21
3	Increased dose primary thromboprophylaxis in ambulatory patients with advanced pancreatic ductal adenocarcinoma, a single centre cohort study. <i>Thrombosis Journal</i> , 2020, 18, 9.	0.9	2
4	The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1940-1951.	1.9	60
5	Prognostic assessment for patients with cancer and incidental pulmonary embolism. <i>Thrombosis Journal</i> , 2018, 16, 8.	0.9	13
6	Treatment and long-term clinical outcomes of incidental pulmonary embolism in cancer patients: an international prospective cohort study. <i>Thrombosis Research</i> , 2018, 164, S193-S194.	0.8	0
7	Advances in managing and preventing thromboembolic disease in cancer patients. <i>Current Opinion in Supportive and Palliative Care</i> , 2017, 11, 347-354.	0.5	5
8	The risk of venous thromboembolism associated with peripherally inserted central catheters in ambulant cancer patients. <i>Thrombosis Journal</i> , 2017, 15, 25.	0.9	43
9	Managing patients with carcinoma of unknown primary: A single UK centre experience. <i>Annals of Oncology</i> , 2017, 28, iii63-iii64.	0.6	0
10	Use of heparins in patients with cancer: individual participant data meta-analysis of randomised trials study protocol. <i>BMJ Open</i> , 2016, 6, e010569.	0.8	18
11	Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 105-113.	1.9	105
12	1600 Incidental pulmonary embolism in cancer: A prognostic score derived from a prospective cohort with uniform management. <i>European Journal of Cancer</i> , 2015, 51, S237-S238.	1.3	1
13	Anticoagulating the subsegmental pulmonary embolism in cancer patients: a survey amongst different medical specialties. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 40, 37-41.	1.0	12
14	Risk of Recurrent Venous Thromboembolism and Major Bleeding in Cancer-Associated Incidental Pulmonary Embolism Amongst Treated and Untreated Patients: A Pooled Analysis of 926 Patients. <i>Blood</i> , 2014, 124, 590-590.	0.6	25
15	Developing a complex intervention for the outpatient management of incidentally diagnosed pulmonary embolism in cancer patients. <i>BMC Health Services Research</i> , 2013, 13, 235.	0.9	10
16	Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. <i>European Journal of Cancer</i> , 2012, 48, 1283-1292.	1.3	273
17	Unsuspected visceral venous thrombosis, in patients with cancer of the gastrointestinal system. <i>Thrombosis Research</i> , 2012, 130, 682-684.	0.8	2
18	Systemic Chemotherapy with Pemetrexed and Cisplatin for Malignant Peritoneal Mesothelioma: A Single Institution Experience. <i>Tumori</i> , 2011, 97, 25-29.	0.6	17

#	ARTICLE	IF	CITATIONS
19	Developments in the systemic treatment of endometrial cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 79, 278-292.	2.0	29
20	Prechemotherapy Serum Levels of CD105, Transforming Growth Factor β 2, and Vascular Endothelial Growth Factor Are Associated With Prognosis in Patients With Advanced Epithelial Ovarian Cancer Treated With Cytoreductive Surgery and Platinum-Based Chemotherapy. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 248-254.	1.2	9
21	Endometrial Cancer: What Is New in Adjuvant and Molecularly Targeted Therapy?. <i>Obstetrics and Gynecology International</i> , 2010, 2010, 1-11.	0.5	40
22	Osteonecrosis of the Jaw after a Single Bisphosphonate Infusion in a Patient with Metastatic Renal Cancer Treated with Sunitinib. <i>Onkologie</i> , 2010, 33, 321-323.	1.1	37
23	Mesenteric desmoid tumor developing on the site of an excised gastrointestinal stromal tumor. <i>Rare Tumors</i> , 2010, 2, 91-93.	0.3	9
24	Weekly Docetaxel with or without Gemcitabine as Second-Line Chemotherapy in Paclitaxel-Pretreated Patients with Metastatic Breast Cancer: A Randomized Phase II Study Conducted by the Hellenic Co-Operative Oncology Group. <i>Oncology</i> , 2009, 77, 212-216.	0.9	9
25	High-dose melphalan and autologous stem cell transplantation as consolidation treatment in patients with chemosensitive ovarian cancer: results of a single-institution randomized trial. <i>Bone Marrow Transplantation</i> , 2008, 41, 547-554.	1.3	9
26	Paclitaxel, epirubicin, and carboplatin in advanced or recurrent endometrial carcinoma: A Hellenic Co-operative Oncology Group (HeCOG) study. <i>Gynecologic Oncology</i> , 2008, 110, 87-92.	0.6	13
27	Paclitaxel, topotecan, and carboplatin in metastatic endometrial carcinoma: A Hellenic Co-operative Oncology Group (HeCOG) study. <i>Gynecologic Oncology</i> , 2008, 111, 27-34.	0.6	6
28	Prognostic and Predictive Factors in Patients with Androgen-Independent Prostate Cancer Treated with Docetaxel and Estramustine: A Single Institution Experience. <i>European Urology</i> , 2008, 53, 323-332.	0.9	18
29	Paclitaxel- and Platinum-Based Postoperative Chemotherapy for Primary Fallopian Tube Carcinoma: A Single Institution Experience. <i>Oncology</i> , 2008, 75, 42-48.	0.9	8
30	5040 POSTER Recurrent or metastatic endometrial cancer: Prognostic factors after taxane-based systemic chemotherapy. <i>European Journal of Cancer, Supplement</i> , 2007, 5, 322.	2.2	0
31	The impact of age in the outcome of patients with advanced or recurrent cervical cancer after platinum-based chemotherapy. <i>Gynecologic Oncology</i> , 2007, 104, 372-376.	0.6	20
32	Biweekly gemcitabine and cisplatin in platinum-resistant/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma. <i>Gynecologic Oncology</i> , 2007, 104, 580-585.	0.6	28
33	Advanced epithelial ovarian cancer in the elderly: chemotherapy tolerance and outcome. <i>Anticancer Research</i> , 2007, 27, 611-7.	0.5	12
34	Anthracycline-based adjuvant chemotherapy in early-stage uterine sarcomas: long-term results of a single institution experience. <i>European Journal of Gynaecological Oncology (discontinued)</i> , 2007, 28, 109-16.	0.3	2
35	Extranodal non-Hodgkin's lymphoma presenting as an abdominal wall mass. A case report and review of the literature. <i>Leukemia and Lymphoma</i> , 2006, 47, 329-332.	0.6	10
36	Non-Hodgkin's Lymphoma of the Renal Pelvis. <i>Clinical Lymphoma and Myeloma</i> , 2006, 6, 404-406.	1.4	9

#	ARTICLE	IF	CITATIONS
37	Brain metastases as isolated site of relapse in patients with epithelial ovarian cancer previously treated with platinum and paclitaxel-based chemotherapy. <i>International Journal of Gynecological Cancer</i> , 2006, 16, 994-999.	1.2	26
38	Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group. <i>BMC Cancer</i> , 2006, 6, 228.	1.1	11
39	Young Age Is Associated with Favorable Characteristics but Is Not an Independent Prognostic Factor in Patients with Epithelial Ovarian Cancer: A Single Institution Experience. <i>Oncology</i> , 2006, 70, 265-272.	0.9	18
40	Prognostic Significance of Magnetic Resonance Imaging (MRI) of Bone Marrow (BM) in Patients with Multiple Myeloma (MM) Undergoing Treatment with High-Dose Melphalan (HDM) and Autologous Stem Cell Transplantation (ASCT).. <i>Blood</i> , 2006, 108, 3095-3095.	0.6	0
41	Carboplatin Hypersensitivity Reactions: A Single Institution Experience. <i>Journal of Chemotherapy</i> , 2005, 17, 104-110.	0.7	16
42	Clinicopathological features of ovarian carcinosarcomas: a single institution experience. <i>Gynecologic Oncology</i> , 2005, 96, 136-142.	0.6	35
43	The outcome of advanced or recurrent non-squamous carcinoma of the uterine cervix after platinum-based combination chemotherapy. <i>Gynecologic Oncology</i> , 2005, 99, 376-382.	0.6	43
44	The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy. <i>Annals of Oncology</i> , 2005, 16, 307-313.	0.6	64
45	Osteonecrosis of the Jaw in Cancer After Treatment With Bisphosphonates: Incidence and Risk Factors. <i>Journal of Clinical Oncology</i> , 2005, 23, 8580-8587.	0.8	990
46	Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: Efficacy, safety, and clinical benefit assessment. <i>Urology</i> , 2005, 65, 126-130.	0.5	26
47	The Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Multiple Myeloma Who Receive Biphosphonates Depends on the Type of Biphosphonate.. <i>Blood</i> , 2005, 106, 637-637.	0.6	15
48	Outcome of patients with advanced non-transitional urothelial carcinomas following platinum-based chemotherapy. <i>Journal of Clinical Oncology</i> , 2005, 23, 4596-4596.	0.8	1
49	Chemotherapy with carboplatin - paclitaxel as the only adjuvant treatment in uterine papillary serous and clear cell carcinoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 5164-5164.	0.8	0
50	Adjuvant chemotherapy with paclitaxel and carboplatin in non-endometrioid carcinoma of the uterus. <i>European Journal of Gynaecological Oncology (discontinued)</i> , 2005, 26, 627-31.	0.3	6
51	Outcome of elderly patients following platinum-based chemotherapy for advanced urothelial cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 4542-4542.	0.8	0